Artia Global Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Artia Global Partners’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-17,400	Closed	-$6.92M	–	52
2025 Q4	$6.92M	Sell	17,400 -17,170	-50%	-$7.6M	0.98%	19
2025 Q3	$15.8M	Buy	34,570 +13,600	+65%	+$5.54M	2.5%	14
2025 Q2	$6.84M	Sell	20,970 -7,630	-27%	-$2.11M	1.65%	13
2025 Q1	$7.72M	Sell	28,600 -27,800	-49%	-$7.14M	1.95%	14
2024 Q4	$13.3M	Buy	56,400 +21,400	+61%	+$5.63M	4.74%	9
2024 Q3	$9.63M	Hold	35,000	–	–	2.62%	8
2024 Q2	$8.51M	Buy	+35,000	New	+$5.53M	1.64%	10
2023 Q4	–	Sell	-15,971	Closed	-$2.83M	–	32
2023 Q3	$2.83M	Hold	15,971	–	–	1.18%	16
2023 Q2	$3.03M	Hold	15,971	–	–	1.05%	23
2023 Q1	$3.2M	Hold	15,971	–	–	1.18%	19
2022 Q4	$3.8M	Buy	+15,971	New	+$3.41M	1.45%	14

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Artia Global Partners's ALNY Position: Q1 2026 in Review

Artia Global Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 17,400 shares — an estimated $6.92M sold.

Artia Global Partners first reported a position in ALNY in Q4 2022 and held it in 11 quarters. The position peaked at $15.8M in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Artia Global Partners reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Artia Global Partners sold 17,400 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $6.92M.
Artia Global Partners first reported a position in Alnylam Pharmaceuticals in Q4 2022 and held it in 11 quarters.
Artia Global Partners's Alnylam Pharmaceuticals position peaked at $15.8M in Q3 2025.
793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Artia Global Partners's 13F filing for Q1 2026, filed 15 May 2026.